Thiazole in the targeted anticancer drug discovery

Adileh Ayati1, Saeed Emami2, Setareh Moghimi1

  • 1Drug Design & Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.

Insights

This review explores thiazole compounds for cancer therapy, detailing their mechanisms of action against cancer cells. It covers chemical designs, structure-activity relationships, and preclinical properties of these promising anticancer agents.

Area of Science:

  • Medicinal Chemistry
  • Organic Chemistry
  • Pharmacology

Background:

  • Cancer remains a leading global cause of mortality, driving the search for novel therapeutic agents.
  • Thiazole heterocycles are integral components of numerous existing drugs and emerging anticancer compounds.
  • Understanding the anticancer potential of thiazole derivatives is crucial for developing new cancer treatments.

Purpose of the Study:

  • To review recent advancements in thiazole-bearing compounds investigated for anticancer properties.
  • To provide a comprehensive overview of their mechanisms of action in cancer cells.
  • To describe chemical designs, structure-activity relationships, and preclinical data.

Main Methods:

  • Literature review of scientific publications on thiazole compounds and cancer therapy.
  • Analysis of chemical structures and their correlation with biological activity.
  • Evaluation of preclinical data regarding efficacy and safety.

Main Results:

  • Thiazole derivatives exhibit diverse mechanisms of action against various cancer types.
  • Structure-activity relationship studies reveal key features for enhanced anticancer potency.
  • Preclinical data indicate promising therapeutic potential for selected thiazole-based agents.

Conclusions:

  • Thiazole-bearing compounds represent a significant class of potential anticancer agents.
  • Further research into their mechanisms and preclinical properties can guide clinical development.
  • Thiazole chemistry offers a versatile scaffold for the design of novel cancer therapeutics.

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
384
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
246
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K